简化登革热疫苗CYD-TDV接种方案的免疫原性与安全性:CYD65随机对照2期非劣效研究
CYD65研究在9-50岁健康人群中比较CYD-TDV一剂、两剂与三剂方案的抗体应答,基線登革血清阳性者中两剂方案对三剂方案在28天和1年时对四个血清型均达到非劣效,安全性与三剂组相似。
要点
- 基线登革血清阳性者中,两剂CYD-TDV对三剂的抗体GMT在28天和1年时各血清型均非劣效。
- 两剂与三剂方案反应原性相似,多数不良事件为非严重全身性。
- 减少剂次可能提高疫苗依从性和覆盖率,尤其在资源有限地区。
核心结论
- 在基线登革血清阳性且年龄≥9岁人群中,两剂CYD-TDV方案可能是获批三剂方案的替代选择。
研究设计与样本
- 随机、对照、2期非劣效研究,在哥伦比亚3个中心和菲律宾3个中心社区招募9-50岁健康人,按1:1:1随机分组,间隔6个月接种。
- 共入组1050人,1048人至少接受一剂注射,993人至少有一次血样(全分析集:三剂组333人、两剂组328人、一剂组332人)。
主要发现
- 两剂对三剂非劣效在各血清型28天和1年时均成立(评估人数:28天两剂272、三剂265;1年两剂190、三剂185)。
- 58名参与者报告60起严重不良事件(三剂组14、两剂组26、一剂组18),多为感染和侵扰或损伤、中毒和操作并发症;无特殊关注的严重不良事件或登革住院,2例死亡与治疗无关。
临床怎么用
- 对基线登革血清阳性且年龄≥9岁者,可考虑两剂CYD-TDV方案以减少接种剂次。
- 减少剂次可能改善疫苗依从性和覆盖率,尤其在资源有限地区。
局限性
- 研究期间方案修订后,仅评估两剂对三剂的非劣效性,未评估一剂对三剂的非劣效性。
- 非劣效性分析仅限于基线登革血清阳性者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three doses of the licensed tetravalent dengue vaccine CYD-TDV (Dengvaxia, Sanofi Pasteur, Lyon France) are immunogenic and effective against symptomatic dengue in individuals aged 9 years and older who are dengue seropositive. Previous trials have provided some evidence that antibody responses elicited after just one dose or two doses of CYD-TDV might be similar to those elicited after three doses. We compared antibody responses following one-dose, two-dose, and three-dose vaccination regimens in individuals who were dengue seropositive at baseline up to 1 year after the last injection. METHODS: In this randomised, controlled, phase 2, non-inferiority study (CYD65), healthy individuals aged 9-50 years were recruited from the community in three sites in Colombia and three sites in the Philippines. Participants were randomly assigned (1:1:1), using a permuted block method with stratification by site and age group, to receive, at 6-month intervals (on day 0, month 6, and month 12), three doses of CYD-TDV (three-dose group), one dose of placebo (on day 0) and two doses of CYD-TDV (at months 6 and 12; two-dose group), or two doses of placebo (on day 0 and month 6) and one dose of CYD-TDV (at month 12; one-dose group). Each dose of CYD-TDV was 0·5 mL, administered subcutaneously into the deltoid of the upper arm. Participants, study staff, investigators, and the funder were masked to group assignment. The co-primary endpoints were geometric mean titres (GMTs) of neutralising antibodies against each dengue virus serotype at 28 days and 1 year after the last vaccine injection. After a protocol amendment during the conduct of the study, the original co-primary objectives of non-inferiority of the one-dose and two-dose groups to the three-dose group were altered to include non-inferiority of the two-dose group to the three-dose group only, to be assessed in individuals who were dengue seropositive at baseline. Non-inferiority was shown if the lower limit of the 95% CI for the ratio of GMTs (GMR) at 28 days and 1 year between groups was more than 0·5 for each serotype. The analysis of the coprimary objectives was done in the per-protocol analysis dataset, which included all participants who had been vaccinated, had no protocol deviations, and had a valid serology test result for at least one dengue serotype at 28 days after the third injection. Safety was assessed throughout in all participants who received at least one injection of study drug, regardless of serostatus. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. FINDINGS: Between May 2, 2016, and Sept 16, 2016, we recruited and enrolled 1050 individuals, of whom 1048 received at least one injection and 993 had at least one blood sample taken (full-analysis dataset; 333 in three-dose group, 328 in two-dose group, and 332 in one-dose group). 860 (86·6%) of 993 participants in the full-analysis dataset were dengue seropositive at baseline. Non-inferiority (two dose vs three dose) was shown for each serotype at both 28 days and 1 year among dengue-seropositive participants (number of participants assessed: 272 [two-dose group], 265 [three-dose group] at 28 days; and 190 [two-dose group], 185 [three-dose group] at 1 year). At 28 days after the last injection, neutralising antibody GMTs were 899 (95% CI 752-1075) in the two-dose group versus 822 (700-964) in the three dose group against dengue serotype 1 (GMR 1·09 [95% CI 0·86-1·39]); 869 (754-1002) versus 875 (770-995) against serotype 2 (GMR 0·99 [0·82-1·20]); 599 (524-685) versus 610 (535-694) against serotype 3 (GMR 0·98 [0·82-1·18]); and 510 (453-575) versus 531 (470-601) against serotype 4 (GMR 0·96 [0·81-1·14]). At year 1, GMTs had decreased but remained above baseline for all serotypes: 504 (95% CI 403-630) in the two-dose group versus 490 (398-604) in the three-dose group against serotype 1 (GMR 1·03 [0·76-1·40]); 737 (611-888) versus 821 (704-957) against serotype 2 (GMR 0·90 [0·71-1·14]); 437 (368-519) versus 477 (405-561) against serotype 3 (GMR 0·92 [0·72-1·16]); and 238 (205-277) versus 270 (235-310) against serotype 4 (GMR 0·88 [0·72-1·09]). Reactogenicity profiles were similar across treatment groups. Most unsolicited adverse events after any injection were non-serious and systemic in nature. During the study, 60 serious adverse events were reported in 58 participants (14 in three-dose group, 26 in two-dose group, 18 in one-dose group), mostly infection and infestations or injury, poisoning, and procedural complications. No serious adverse events of special interest or admissions to hospital for dengue occurred. Two deaths occurred, unrelated to study treatment. INTERPRETATION: A two-dose CYD-TDV regimen might be an alternative to the licensed three-dose regimen in individuals who are dengue seropositive at baseline and aged 9 years and older. Vaccination with a reduced number of doses could lead to improved vaccine compliance and coverage, especially in low-resource settings. FUNDING: Sanofi Pasteur.
引用
- Coronel-MartÍnez DL, Park J, López-Medina E, et al. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study. Lancet Infect Dis. 2020. PMID: 33212067. doi:10.1016/S1473-3099(20)30767-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。